AN-9 (Titan)

Erole Hobdy, John Murren

Curr Opin Investig Drugs. 2004 Jun;5(6):628-34.

PMID: 15242252

Abstract:

Titan is developing AN-9 for the potential treatment of various cancers. AN-9 is a histone deacetylase inhibitor analog of butyric acid that causes apoptosis of cancer cells through signaling cellular differentiation. In March 2001, a phase I/II study involving patients with liver tumors was initiated. By November 2001, enrollment had been completed in a second phase II study of refractory non-small-cell lung cancer (NSCLC). In June 2003, Titan began enrollment for a phase IIb trial of AN-9 in combination with docetaxel in patients with NSCLC.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP122110536	AN-9		122110-53-6	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: